Skip to main content Back to Top
Advertisement

7/14/2020

Hydroxychloroquine Sulfate Tablets

Products Affected - Description

    • Hydroxychloroquine sulfate tablet, Dr. Reddy's, 200 mg, 100 count, NDC 43598-0721-01
    • Hydroxychloroquine sulfate tablet, Dr. Reddy's, 200 mg, 500 count, NDC 43598-0721-05
    • Hydroxychloroquine sulfate tablet, Major, 200 mg, 50 count, NDC 00904-6884-06
    • Hydroxychloroquine sulfate tablet, Major, 200 mg, 100 count, NDC 00904-6884-61
    • Hydroxychloroquine sulfate tablet, Rising Pharmaceuticals, 200 mg, 100 count, NDC 42385-0927-01
    • Hydroxychloroquine sulfate tablet, Rising Pharmaceuticals, 200 mg, 500 count, NDC 42385-0927-05
    • Hydroxychloroquine sulfate tablet, Sandoz, 200 mg, 500 count, NDC 00781-5994-05
    • Hydroxychloroquine sulfate tablet, Teva, 200 mg, 100 count, NDC 00591-3041-01
    • Hydroxychloroquine sulfate tablet, Teva, 200 mg, 500 count, NDC 00591-3041-05
    • Hydroxychloroquine sulfate tablet, Zydus, 200 mg, 100 count, NDC 68382-0096-01
    • Hydroxychloroquine sulfate tablet, Zydus, 200 mg, 500 count, NDC 68382-0096-05

Reason for the Shortage

    • Amneal had hydroxychloroquine 200 mg tablets on shortage due to increased demand.
    • Concordia has Plaquenil 200 mg tablets available.
    • Dr. Reddy's did not provide a reason for the shortage.
    • Major has temporarily discontinued hydroxychloroquine tablets.
    • Mylan has hydroxychloroquine 200 mg tablets available.
    • Prasco had hydroxychloroquine 200 mg tablets on shortage due to increased demand.
    • Rising has hydroxychloroquine tablets on shortage due to increased demand.
    • Sandoz has donated product to support the COVID-19 pandemic response. Additional information is available at https://www.sandoz.com/news/media-releases/novartis-commits-donate-130-million-doses-hydroxychloroquine-support-global
    • Sandoz is allocating remaining hydroxychloroquine tablets.
    • Sun Pharma did not provide a reason for the shortage.
    • Teva has hydroxychloroquine tablets on shortage due to increased demand.
    • Zydus has hydroxychloroquine 200 mg tablets on shortage due to increased demand.

Available Products

    • Plaquenil tablet, Concordia, 200 mg, 100 count, NDC 24987-0562-10
    • Hydroxychloroquine sulfate tablet, Amneal, 200 mg, 100 count, NDC 69238-1544-01
    • Hydroxychloroquine sulfate tablet, Mylan, 200 mg, 100 count, NDC 00378-0373-01
    • Hydroxychloroquine sulfate tablet, Prasco, 200 mg, 100 count, NDC 66993-0057-02
    • Hydroxychloroquine sulfate tablet, Prasco, 200 mg, 500 count, NDC 66993-0057-04
    • Hydroxychloroquine sulfate tablet, Sandoz, 200 mg, 100 count, NDC 00781-5994-01
    • Hydroxychloroquine sulfate tablet, Sun Pharma, 200 mg, 100 count, NDC 57664-0761-88
    • Hydroxychloroquine sulfate tablet, Sun Pharma, 200 mg, 500 count, NDC 57664-0761-13

Estimated Resupply Dates

    • Amneal has hydroxychloroquine 200 mg tablets in 100 count available. Amneal is also allocating supplies to Health Warehouse online pharmacy. The pharmacy will confirm the product has been prescribed for an FDA approved indication before filling any prescriptions. Orders can be placed at https://try.healthwarehouse.com/hydroxy/ or by calling 800-748-7001.
    • Dr. Reddy's has hydroxychloroquine 200 mg tablets in 100 and 500 count bottles on allocation to contracted customers.
    • Major has hydroxychloroquine 200 mg tablets in 50 count and 100 count on back order and the company cannot estimate a release date.
    • Rising has hydroxychloroquine 200 mg tablets in 100 count and 500 count bottles on intermittent back order and the company is allocating product when it becomes available.
    • Sandoz has hydroxychloroquine 200 mg tablets in 500 count bottles on back order and the company cannot estimate a release date.
    • Teva has hydroxychloroquine 200 mg tablets in 100 count and 500 count on back order and the company estimates release dates in late-July 2020 for the 100 count bottles and late-August 2020 for the 500 count bottles.
    • Zydus has hydroxychloroquine 200 mg tablets in 100 count and 500 count bottles on allocation to current customers.

Implications for Patient Care

    • ASHP has provided stewardship recommendations for off-label use of this treatment for COVID-19. https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/Coronavirus/docs/Stewardship-of-Off-Label-Treatments.ashx

Updated

Updated July 14, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 19, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.